Global Pegfilgrastim Biosimilars Market Size to Grow at a CAGR of 7% in the Forecast Period of 2023-2031

The ‘Global Pegfilgrastim Biosimilars Market Report and Forecast 2023-2031’ by Expert Market Research gives an extensive outlook of the global pegfilgrastim biosimilars market analysis, assessing the market on the basis of its segments like indication type, product type, application, distribution channel, and major regions.

The report also provides a detailed insight of the market on the basis of patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnership and collaborations analysis.

Pegfilgrastim Biosimilars Market Share, Size, Price, Growth, Trends, Industry Report, Key Player, Major Segments and Forecast

The key highlights of the report include:

Market Overview (2016-2031)

  • Forecast CAGR (2023-2031): 7%

Growing demand for cost-effective alternatives to biologic drugs is expected to drive the growth of the global pegfilgrastim biosimilars market. The increasing prevalence of cancer and the need for supportive care treatments like neutropenia management offer lucrative growth opportunities to the market. However, challenges in manufacturing processes and regulatory complexities might pose challenges for the pegfilgrastim biosimilars market.

Get a Free Sample Report with Table of Contents@

The patent expiration of Neulasta®, a pegfilgrastim drug produced by Amgen, has led to the development of various biosimilars, opening new growth opportunities for the market. These developments, coupled with the growing demand for affordable treatments and strengthening healthcare infrastructure, are likely to contribute to the global pegfilgrastim biosimilars market growth.

Pegfilgrastim Biosimilars Industry Definition and Major Segments

Pegfilgrastim is a PEGylated form of recombinant human granulocyte colony-stimulating factor (G-CSF) analog filgrastim. It is used to stimulate the production of white blood cells, specifically neutrophils, to reduce the risk of infection in patients undergoing chemotherapy. Pegfilgrastim biosimilars are highly similar versions of the original pegfilgrastim drugs, with no clinically meaningful differences in terms of safety and efficacy.

Read Full Report with Table of Contents@

Based on indication type, the market is segmented into:

  • Neutropenia
  • Hematopoietic Subsyndrome
  • Others

Based on product type, the market is segmented into:

  • MK-6302
  • Peg G-CSF
  • PEG Neutrogena
  • Grasustek
  • LA-EP2006
  • R-TPR-029
  • Filgrastim
  • Others

Based on application, the market is classified into:

  • Oncology
  • Chronic and Autoimmune Diseases
  • Others

Based on distribution channel, the market is bifurcated into:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Based on region, the market is segregated into:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

Pegfilgrastim Biosimilars Market Trends

The key trends in the global pegfilgrastim biosimilars market include the growing development and research by the pharmaceutical sector, aimed towards the development of affordable biosimilar drugs. Increased clinical trials for pegfilgrastim biosimilars are projected to drive market growth. Additionally, strategic collaborations between pharmaceutical companies to enhance their biosimilars portfolio are anticipated to impact the growth of the market positively.

The rising prevalence of cancer and the increasing demand for cost-effective treatment options are major factors driving the pegfilgrastim biosimilars market. In addition, favorable government policies and initiatives to promote the use of biosimilars are expected to boost the growth of the market.

Key Market Players

The major players in the global pegfilgrastim biosimilars market report are Merck & Co., Inc., Biocon Limited, Sandoz International GmbH, Intas Pharmaceuticals Ltd., Mylan N.V., Fresenius Kabi AG, Apotex Inc., and Pfizer Inc., among others. The report covers the market shares, capacities, plant turnarounds, expansions, investments, and mergers and acquisitions, among other latest developments of these market players.

The report studies the latest updates in the market, along with their impact across the market. It also analyzes the market demand, together with its price and demand indicators. The report also tracks the market based on SWOT and Porter’s Five Forces Models.

Read More Reports:

Global Bruton’s Tyrosine Kinase (BTK) Inhibitors Market:

South Korea Instant Coffee Market:

Global Vasomotor Symptoms Treatment Market:

Global Acute Myeloid Leukemia Treatment Market:

Global Transthyretin Amyloidosis Treatment Market: